Patients with Hepatitis C treated with pegylated interferon and Ribavirin
Keywords:
hepatitis c virus, pegylated interferon, ribavirinAbstract
Introduction: Hepatitis C is a necroinflammatory disease of the liver caused by the virus of the same name; it progresses to chronicity in most cases causing irreversible and sometimes fatal sequelae.
Objective: To characterize clinically-epidemiologically the patients who were being treated with Pegylated Interferon and Ribavirin and how they influence their evolution according to individual risk factors.
Method: A quasi-experimental research was carried out in patients diagnosed with Viral Hepatitis C, treated at the Hepatitis Consultation of the "Saturnino Lora" Provincial Hospital in Santiago de Cuba, in the period from September 1, 2020 to November 31, 2022.
Results: There was a predominance of the intermediate ages of life, the gender that presented the highest frequency was the female, operations and previous transfusions constituted the main routes of transmission.
Conclusions: There were no significant differences in relation to the epidemiological and clinical characteristics in the patients studied, with respect to what the national and international literature reports, except for the prevalence of the female sex and that the evolution in most cases was favorable.
Downloads
References
Arredondo Bruce A, Perez Trujillo E. Nuevos progresos en el enfrentamiento a la hepatitis C. Rev Med Electrón. 2020 [citado 21/02/2022];40(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242020000200014
The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176. Disponible en: https://doi.org/10.1016/S2468-1253(16)30181-9
European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325–336. Disponible en: https://doi.org/10.1016/S2468-1253(17)30045-6
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996–1005. Disponible en: https://doi.org/10.1053/j.gastro.2017.06.012
Bari K, Luckett K, Kaiser T, Diwan T, Cuffy M, Schoech M, et al. Hepatitis C transmission from seropositive, non-viremic donors to non-hepatitis C liver transplant recipients. Hepatology 2020;67:1673–1682. Disponible en: https://doi.org/10.1002/hep.29704
Van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, et al. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. Lancet Gastroenterol Hepatol 2020;3:856–864. Disponible en: https://doi.org/10.1016/S2468-1253(18)30271-1
Hellard M, Rolls DA, Sacks Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014;60:1861–1870. Disponible en: https://doi.org/10.1002/hep.27403
Lawitz E, Landis CS, Flamm SL, Bonacini M, Ortiz-Lasanta G, Huang J, et al. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet Gastroenterol Hepatol. 2022 Oct;5(10):918-926. Disponible en: https://doi.org/10.1016/S2468-1253(19)30417-0
Martinot Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122–1126. Disponible en: https://doi.org/10.1002/hep.23444
Chen CP, Cheng CY, Zou H, Cheng CH, Cheng SH, Chen CK, et al. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings. J Microbiol Immunol Infect. 2019 Aug;52(4):556-562. Disponible en: https://doi.org/10.1016/j.jmii.2020.10.002
Garioud A, Heng R, Amiot X, Rémy AJ, Ollivier-Hourmand I, Mokhtari C, et al. Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients. Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1270-1274. Disponible en: https://doi.org/10.1097/MEG.0000000000001450
Traebert J, Porton Fratoni KR, Cabral Domingos da Rosa L, Traebert E, Ceola Schneinder IJ. The burden of hepatitis C infection in a Southern Brazilian State. Rev Soc Bras Med Trop. 2020 [citado 07/05/2019];51(5):670-3. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000500670&lng=en&tlng=en.
Kimble M M, Javanbakht M, Chew KW, et al. Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. BMC Infect Dis 19, 626 (2019). Disponible en: https://doi.org/10.1186/s12879-019-4223-9
Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis. 2019 Sep 14;19(1):809. Disponible en: https://doi.org/10.1186/s12879-019-4403-7
Fridriksson B, Bergmann OM, Olafsson S. Treatment of hepatitis C with peginterferon and ribavirin in Iceland from 2002-2012. Laeknabladid. 2017 Mars;103(3):125-128. Icelandic. Disponible en: https://doi.org/10.17992/lbl.2017.03.126
Sidorkiewicz M, Grek-Kowalinska M, Piekarska A. Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment. Pathogens. 2022 Jun 25;9(6):514. Disponible en: https://doi.org/10.3390/pathogens9060514
Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, et al. Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study. Gut Liver. 2017 Mar 15;11(2):270-275. Disponible en: https://doi.org/10.5009/gnl16163
Al-Ghamdi SMG, Alaulaqi N, Al-Amoudi AA, Alghamdi A, Zagnoon A, Sadiq BB. Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection. Saudi J Kidney Dis Transpl. 2017 Jul-Aug;28(4):799-805. PMID: 28748882.
Tan SS, Adlin Nadia Z. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care. Med J Malaysia. 2017 Jun;72(3):165-174. PMID: 28733564.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016; 64:1217–1223.Gastroenterology 2020;155:411–421. Disponible en: https://doi.org/10.1016/j.jhep.2016.01.034
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Margarita Montes de Oca Carmenaty
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licencia Creative Commons
La Revista Cubana de Medicina Tropcial se encuentra bajo una
Este sitio está bajo Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
